MBB Public Markets I LLC Makes New $3.15 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

MBB Public Markets I LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 27,792 shares of the medical device company’s stock, valued at approximately $3,151,000.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after acquiring an additional 136,282 shares in the last quarter. Capital Research Global Investors boosted its position in DexCom by 21.4% during the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the period. Sands Capital Management LLC boosted its position in DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after purchasing an additional 1,398,136 shares during the period. Capital World Investors boosted its position in DexCom by 130.7% during the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares during the period. Finally, Blair William & Co. IL boosted its position in DexCom by 1.4% during the 1st quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock valued at $628,684,000 after purchasing an additional 64,683 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. Insiders have sold 1,824 shares of company stock worth $126,390 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Down 0.4 %

Shares of DexCom stock opened at $67.29 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $26.76 billion, a PE ratio of 43.41, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The stock’s fifty day moving average is $73.66 and its 200-day moving average is $107.43.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $0.34 earnings per share. DexCom’s revenue for the quarter was up 15.3% compared to the same quarter last year. Equities analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on DXCM shares. Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Royal Bank of Canada reduced their price objective on DexCom from $165.00 to $145.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Stifel Nicolaus boosted their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Barclays reduced their price target on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Finally, Oppenheimer reduced their price target on DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.